140 related articles for article (PubMed ID: 10524571)
21. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21].
Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C
Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636
[TBL] [Abstract][Full Text] [Related]
22. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
23. [Thyroid carcinoma].
Tamaki H
Gan To Kagaku Ryoho; 2005 Apr; 32(4):561-5. PubMed ID: 15853229
[TBL] [Abstract][Full Text] [Related]
24. Predictive factors of carcinoma in 327 patients with follicular neoplasm of the thyroid.
Besic N; Sesek M; Peric B; Zgajnar J; Hocevar M
Med Sci Monit; 2008 Sep; 14(9):CR459-67. PubMed ID: 18758416
[TBL] [Abstract][Full Text] [Related]
25. Expression of D2-40 in adjunct diagnosis of papillary thyroid carcinoma.
Wang SL; Li SH; Chen WT; Chai CY
APMIS; 2007 Aug; 115(8):906-10. PubMed ID: 17696946
[TBL] [Abstract][Full Text] [Related]
26. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
Zöphel K; Wunderlich G; Smith BR
Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic evaluation of alanine aminopeptidase as serum marker for detecting cancer.
Severini G; Gentilini L; Tirelli C
Cancer Biochem Biophys; 1991 Nov; 12(3):199-204. PubMed ID: 1688253
[TBL] [Abstract][Full Text] [Related]
29. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
Tarle M
Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
[TBL] [Abstract][Full Text] [Related]
30. Clinical usefulness of positron emission tomography-computed tomography in recurrent thyroid carcinoma.
Razfar A; Branstetter BF; Christopoulos A; Lebeau SO; Hodak SP; Heron DE; Escott EJ; Ferris RL
Arch Otolaryngol Head Neck Surg; 2010 Feb; 136(2):120-5. PubMed ID: 20157055
[TBL] [Abstract][Full Text] [Related]
31. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study.
Franke WG; Zöphel K; Wunderlich GR; Mat R; Kühne A; Schimming C; Kropp J; Bredow J
Cancer Detect Prev; 2000; 24(6):524-30. PubMed ID: 11198265
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a new highly sensitive immunometric assay for thyroglobulin with reduced interference from autoantibodies.
Broughton MN; Nome R; Sandven I; Paus E; Bjøro T
Tumour Biol; 2016 Jun; 37(6):7729-39. PubMed ID: 26695140
[TBL] [Abstract][Full Text] [Related]
33. Clinical value of serum tumour markers TPA, TPS, TAG 12, CA 15-3 and MCA in breast cancer diagnosis; results from a prospective study.
Eskelinen M; Hippeläinen M; Kettunen J; Salmela E; Penttilä I; Alhava E
Anticancer Res; 1994; 14(2B):699-703. PubMed ID: 8010729
[TBL] [Abstract][Full Text] [Related]
34. Serum tumor markers in colorectal cancer staging, grading, and follow-up.
Plebani M; De Paoli M; Basso D; Roveroni G; Giacomini A; Galeotti F; Corsini A
J Surg Oncol; 1996 Aug; 62(4):239-44. PubMed ID: 8691835
[TBL] [Abstract][Full Text] [Related]
35. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
[TBL] [Abstract][Full Text] [Related]
36. Tumor markers and oncogene expression in thyroid cancer using biochemical and immunohistochemical studies.
Hashimoto T; Matsubara F; Mizukami Y; Miyazaki I; Michigishi T; Yanaihara N
Endocrinol Jpn; 1990 Apr; 37(2):247-54. PubMed ID: 1699752
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.
Robbins RJ; Srivastava S; Shaha A; Ghossein R; Larson SM; Fleisher M; Tuttle RM
J Clin Endocrinol Metab; 2004 Dec; 89(12):6010-6. PubMed ID: 15579752
[TBL] [Abstract][Full Text] [Related]
38. Significance of postoperative serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas.
Lin JD; Huang MJ; Hsu BR; Chao TC; Hsueh C; Liu FH; Liou MJ; Weng HF
J Surg Oncol; 2002 May; 80(1):45-51. PubMed ID: 11967907
[TBL] [Abstract][Full Text] [Related]
39. Recurrent differentiated thyroid cancer without elevation of serum thyroglobulin.
Westbury C; Vini L; Fisher C; Harmer C
Thyroid; 2000 Feb; 10(2):171-6. PubMed ID: 10718555
[TBL] [Abstract][Full Text] [Related]
40. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
